Complications of immunotherapy in advanced hepatocellular carcinomaopen accessComplications of immunotherapy in advanced hepatocellular carcinoma
- Other Titles
- Complications of immunotherapy in advanced hepatocellular carcinoma
- Authors
- 송영기; 유정주; 김상균; 김영석
- Issue Date
- Mar-2024
- Publisher
- 대한간암학회
- Keywords
- Immune checkpoint inhibitors; Immunotherapy; Carcinoma; hepatocellular; Side effect; drug
- Citation
- Journal of Liver Cancer, v.24, no.1, pp 9 - 16
- Pages
- 8
- Journal Title
- Journal of Liver Cancer
- Volume
- 24
- Number
- 1
- Start Page
- 9
- End Page
- 16
- URI
- https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/26109
- DOI
- 10.17998/jlc.2023.11.21
- ISSN
- 2288-8128
2383-5001
- Abstract
- Immune checkpoint inhibitors (ICIs) are highly effective in cancer treatment. However, the risks associated with the treatment must be carefully balanced against the therapeutic benefits. Immune-related adverse events (irAEs) are generally unpredictable and may persist over an extended period. In this review, we analyzed common irAEs reported in highly cited original articles and systematic reviews. The prevalent adverse reactions include fatigue, pyrexia, rash, pruritus, diarrhea, decreased appetite, nausea, abdominal pain, constipation, hepatitis, and hypothyroidism. Therefore, it is crucial to conduct evaluations not only of gastrointestinal organs but also of cardiac, neurologic, endocrine (including the frequently affected thyroid), and ophthalmic systems before commencing ICIs. This review further explores commonly reported types of irAEs, specific irAEs associated with each ICI agent, rare yet potentially fatal irAEs, and available treatment options for managing them.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Internal Medicine > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/26109)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.